Table 4.
Hazard ratios (%) for outcomes three and twelve months after last M/E measurement. Model 1: eGFR and M/E only; Model 2: adjusted for age, sex and comorbidity
| Model 1 | Model 2 | ||||
|---|---|---|---|---|---|
| All patients | eGFR 10–15 | All patients | eGFR 10–15 | ||
| 12 month analysis | |||||
| Dialysis | eGFR | 83 (81–85)c | 77 (69–87)c | 82 (80–84)c | 76 (68–85)c |
| M/E | 113 (91–140) | 98 (71–134) | 103 (82–128) | 81 (57–115) | |
| Death | eGFR | 96 (93–98)c | 108 (91–128) | 94 (92–97)c | 107 (90–127) |
| M/E | 22 (14–33)c | 21 (11–40)c | 26 (16–41)c | 22 (11–45)c | |
| Combined | eGFR | 88 (86–89)c | 85 (78–93)c | 87 (85–88)c | 84 (77–93)c |
| M/E | 75 (62–92)a | 70 (52–93)a | 75 (61–92)b | 63 (46–87)b | |
| 3 month analysis | |||||
| Dialysis | eGFR | 79 (77–82) | 79 (67–93)b | 79 (76–82)c | 78 (66–92)b |
| M/E | 77 (57–104) | 31 (17–53)c | 70 (52–94)a | 26 (15–44)c | |
| Death | eGFR | 96 (93–99)b | 116 (94–142) | 94 (92–97)c | 114 (92–142) |
| M/E | 13 (7–22)c | 9 (4–21)c | 14 (8–27)c | 9 (3–23)c | |
| Combined | eGFR | 87 (85–88)c | 91 (80–103) | 86 (84–88)c | 91 (80–103) |
| M/E | 48 (36–63)c | 20 (13–33)c | 49 (37–64)c | 20 (13–33)c | |
a:p < 0.05; b:p < 001;c:p < 0.001